Filter By

Case Study Clear All Filters

download

Case Study

Data Collection Efficiency for a Novel Anti-Infective Therapy

Learn how we improved data collection efficiency through thoughtful database design that allowed the sponsor to overcome a complex trial challenge and transition ...

download

Case Study

Rapid Launch of a Phase I COVID-19 Vaccine Trial

Learn how the Veristat team quickly mobilized to help a sponsor get their clinical trial databased designed and launched in two weeks in order to achieve ...

download

Case Study

Overcoming an NDA Refusal To File

Learn how the right biostatistical experts performed a quality review of the clinical data for an NDA that received a Refusal-to-File from the FDA

download

Case Study

Preparing Data for a Marketing Authorization Application (MAA)

Read the case study to learn how we helped a biotech prepare the MAA submission for a recently acquired product. Our creative approach included utilizing one DB for ...

download

Case Study

Rescue Patient Recruitment for Lagging Trial

Patient recruitment delays are common challenges in clinical trials that can lead to costly delays. In fact, nearly 80 percent of patient recruitment timelines in ...

download

Case Study

Veristat Works Well with Growing Firms

We are more than just your typical boutique "CRO" that caters to growing firms. Meet us and consider why you should speak with Veristat for the design and ...

download

Case Study

Understanding and Operationalizing A Complex Adaptive Design

A clinical-stage biopharmaceutical company came to Veristat with a complex statistical methodology for running a phase II adaptive design trial with the goal of ...

download

Case Study

Guiding an Oncology Program to Success

A clinical stage biotech firm engaged Veristat to run their very first ever clinical trial, a phase I US only oncology trial. When the project started, the client was ...

download

Case Study

Quick Feasibility Assessment to Expand Trial Into Europe

Veristat provides a feasibility assessment to a clinical stage biotechnology firm who wants to know whether it is feasible  to expand their current US study into ...